晚期卵巢癌新辅助化疗疗效分析及其对预后的影响  

Effect and prognostic analysis of applying neoadjuvant chemotherapy in advanced ovarian cancer

作　　者：李雪兵[1] 王前[1] 李新国[1] 张怡[1] 曹兰琴[1] 

机构地区：[1]中南大学湘雅医院护理部妇产科,湖南长沙410008

出　　处：《中国现代医学杂志》2011年第33期4203-4206,共4页China Journal of Modern Medicine

摘　　要：目的探讨术前新辅助化疗在晚期卵巢癌治疗中的疗效及其对预后的影响。方法回顾性分析326例晚期卵巢癌患者,按照直接手术减瘤和新辅助化疗后再减瘤分为两组,比较化疗疗效和预后相关指标。方法新辅助化疗组中,CR+PR87例(58.7%),IP55例(37.2%),SD6例(4.1%)。新辅助化疗组平均术中出血量明显少于术前未化疗组(P<0.05);新辅助化疗组平均手术时间较术前未化疗组缩短,两组比较有显著性差异(P<0.05)。新辅助化疗组满意减瘤率明显高于术前未化疗组(P<0.05)。两组1、3、5年存活率差异无显著性意义(P>0.05)。结论新辅助化疗使晚期卵巢癌手术满意减瘤率提高,但1、3、5年生存率改善不明显。[ Objective ] To explore the effect and prognostic analysis of neoadjuvant chemotherapy in advanced ovarian cancer. [Methods] 326 patients with advanced ovarian cancer were analyzed retrospectively, and were di- vided into two groups according to whether they had received neoadjuvant chemotherapy or not before operation, the effeet of chemotherapy and prognostic factors were analyzed. [ Results ] 87 patients showed CR and PR, 55 patients showed IP, 6 patients showed SD in neoadjuvant chemotherapy group. The amount of bleeding and time of operation in neoadjuwmt chemotherapy group was significantly less than those of without neoadjuvant chemotherapy group （P 〈 0.05）; The optimal cytoreduetive surgery rate in neoadjuvant chemotherapy group was 76.4%. Which was significantly higher than that of without neoadjuvant chemotherapy group （37.6%）（P 〈0.05）; There was no significant difference in 1, 3, 5 year survival rates between two groups. [ Conclusion ] Neoadjuvant chemotherapy can improve optimal cytoreducfion surgery rate, but not improve survival rates significantly.

关 键 词：卵巢癌 新辅助化疗 化疗疗效 预后 

分 类 号：R737.31[医药卫生—肿瘤]